Article content continued
Last fall, French government officials announced that the medical cannabis study, which begins in March, will enroll 3,000 patients. All products available under the study, monitored by the French Ministry of Health and Solidarity, were expected to be smoke-free, such as cannabis oils, tinctures and capsules.
To ensure that enough products are available, both main and replacement suppliers have been secured. For the Canadian companies, Aurora will supply three lots as the main supplier and Tilray two lots as the main supplier and two as a substitute supplier, according to Marihuana Business Daily.
Photo by Getty Images
In general, the drugs fall under three umbrella groups: THC dominant, THC / CBD balanced, and CBD dominant.
Under the THC-dominant classification, ANSM reports that Aurora and Tilray will act as main and substitute suppliers for cannabis flowers with more than eight percent THC and less than one percent CBD. In addition, Tilray will be a major supplier of another THC-dominant batch, namely sublingual oil with more than five milligrams of THC and less than one mg of CBD per millimeter.
In terms of THC / CBD balanced products, Aurora and Tilray will once again be primary and substitute suppliers for flowers that offer more than five percent of THC and CBD. For another batch in the same category, Tilray will be a major supplier of sublingual oil with over five mg of THC and five mg of CBD per ml.
For CBD-dominant products, Aurora will be a major supplier of flowers that contain less than five percent THC and more than five percent CBD.